Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 15, 26 | Tobin James R | director | M-Exempt | 15,000 @ $63.68 | $955.2K |
Daily · Wilder smoothing
| Sep 15, 26 |
| Tobin James R |
| director |
| M-Exempt |
| 15,000 @ $53.75 |
| $806.3K |
| Sep 15, 26 | Tobin James R | director | M-Exempt | 15,000 @ $53.75 | $806.3K |
| Sep 15, 26 | Tobin James R | director | M-Exempt | 15,000 @ $63.68 | $955.2K |
| Sep 15, 26 | Tobin James R | director | S-Sale | 30,000 @ $74.58 | $2.24M |
| Aug 18, 26 | Zarrilli Stephen T | director | M-Exempt | 25,000 @ $53.27 | $1.33M |
| Aug 18, 26 | Zarrilli Stephen T | director | S-Sale | 25,000 @ $87.04 | $2.18M |
| Aug 18, 26 | Zarrilli Stephen T | director | M-Exempt | 25,000 @ $53.27 | $1.33M |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 63.07 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 91.57 | Oscillator | Sell |
| Williams %R (14) | -6.34 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.87 (Hist 0.80) | Oscillator | Strong Buy |
| Average Directional Index (14) | 22.22 (+DI 32.8 / -DI 12.7) | Trend | Buy |
| EMA 20 | 77.42 | MA | Strong Buy |
| SMA 20 | 76.54 | MA | Strong Buy |
| EMA 50 | 77.76 | MA | Strong Buy |
| SMA 50 | 78.15 | MA | Strong Buy |
| SMA 200 | 83.79 | MA | Sell |
FY2024 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck right now?
AUDUBON, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will highlight its latest spine innovations at the 41st Annual North American Spine Society (NASS) Meeting in San Antonio, Texas, from October 14-17.
AUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2026 after the market close on Thursday, November 5, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
GMED gains musculoskeletal share on strong spine and trauma growth, while product innovation and a debt-free balance sheet support its appeal.
Globus Medical, Intuitive Surgical and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 1.10 | 1.34 | Beat 21.8% | $789.6M |
| May 7, 2026 | 0.92 | 1.12 | Beat 21.7% | $759.9M |
| Feb 24, 2026 | 1.06 | 1.28 | Beat 20.8% | $826.4M |
| Nov 6, 2025 | 0.78 | 1.18 | Beat 51.1% | $769.0M |
| Aug 7, 2025 | 0.76 | 0.86 | Beat 13.2% | $745.3M |
| May 8, 2025 | 0.74 | 0.68 | Miss -8.6% | $598.1M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 16, 2026 | 2026-09-16 16:35:39 | View |
| 144 | Sep 15, 2026 | 2026-09-15 14:28:48 | View |
| 4 | Aug 19, 2026 | 2026-08-19 17:07:55 | View |
| 144 | Aug 18, 2026 | 2026-08-18 16:23:32 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 17:06:03 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:19:48 | View |
| 4 | Jul 28, 2026 | 2026-07-28 18:22:52 | View |
| 4 | Jun 9, 2026 | 2026-06-09 17:04:17 | View |
| 4 | Jun 8, 2026 | 2026-06-08 17:14:27 | View |
| 144 | Jun 5, 2026 | 2026-06-05 15:15:36 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | GMED | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 20.5x | 53.5x · sector 20.7x | In line |
| Forward P/E (FY26E) | 16.3x | EPS est. 5.00 | Discount |
| Price / Book | 2.3x | 3.0x | Discount |
| Price / Sales | 3.5x | 5.4x | Discount |
| EV / EBITDA | 11.1x | 20.9x | Discount |
| Return on equity | 11.6% | — | Healthy |
| Gross margin | 68.5% | 68.1% | In line |
| Debt / Equity | 0.02 | 0.06 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 10.85 | Safe zone |
Discounted cash flow model
Current price $81.41
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 1, 26 | RBC Capital | maintain | Outperform | Outperform |
| Aug 7, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Jul 16, 26 | Truist Securities | maintain | Buy | Buy |
| Jul 13, 26 | RBC Capital | maintain | Outperform | Outperform |
| Jul 8, 26 | Stifel | maintain | Hold | Hold |
| Jun 15, 26 | Piper Sandler | maintain | Overweight | Overweight |
| May 8, 26 | Wells Fargo | maintain | Overweight | Overweight |
| May 8, 26 | Needham | maintain | Buy | Buy |
| May 8, 26 | RBC Capital | maintain | Outperform | Outperform |